Patient characteristics and patient-reported and physician-reported outcomes in patients with inflammatory rheumatic disease
| RA | AS | PMR | SLE | pSS | IIM | SSc | |
| No of cases with valid RAID | 7826 | 1532 | 1105 | 1142 | 301 | 106 | 386 |
| Female (%) | 74 | 42 | 64 | 89 | 89 | 58 | 76 |
| Age in years | 63±14 | 51±14 | 73±8 | 47±15 | 53±16 | 58±14 | 58±14 |
| Disease duration in years | 13.3±10.8 | 17.7±13 | 5.4±6.3 | 15.4±10.3 | 11.7±8.9 | 11.3±8.1 | 12.4±10.2 |
| RAID | 3.6±2.3 | 4.0±2.3 | 3.2±2.3 | 3.0±2.4 | 3.4±2.4 | 3.5±2.5 | 3.8±2.3 |
| RAID, unweighted | 3.6±2.3 | 4.0±2.3 | 3.2±2.3 | 3.0±2.4 | 3.4±2.4 | 3.5±2.4 | 3.8±2.3 |
| PtGl health status | 4.2±2.3 n=7660 | 4.4±2.2 n=1507 | 4.1±2.3 n=1063 | 3.6±2.4 n=1080 | 4.1±2.3 n=286 | 4.2±2.5 n=105 | 4.6±2.1 n=370 |
| PtGl disease activity | 3.7±2.4 n=7694 | 4±2.4 n=1509 | 3.8±2.7 n=1055 | 2.7±2.5 n=1123 | 3.5±2.6 n=285 | 3.7±2.5 n=102 | 4.1±2.3 n=369 |
| PhGl disease activity | 1.8±1.9 n=7657 | 2.2±1.9 n=1438 | 1.0±1.4 n=1092 | 1.6±1.3 n=1101 | 1.8±1.3 n=293 | 1.8±1.6 n=105 | 2.2±1.6 n=373 |
| EQ-5D | 0.77±0.2 n=7589 | 0.77±0.2 n=1504 | 0.79±0.2 n=1071 | 0.85±0.2 n=1115 | 0.80±0.2 n=295 | 0.76±0.3 n=104 | 0.76±0.2 n=374 |
| WHO-5 | 57±25 n=4711 | 53±23 n=782 | 56±26 n=540 | 58±25 n=640 | 57±25 n=139 | 60±26 n=47 | 53±24 n=129 |
All values are mean±SD unless otherwise indicated.
AS, ankylosing spondylitis; EQ-5D, EuroQoL-5 Dimensions; IIM, idiopathic inflammatory myositis; PMR, polymyalgia rheumatica; pSS, primary Sjögren’s syndrome; PtGl, Patient Global; RA, rheumatoid arthritis; RAID, rheumatoid arthritis impact of disease; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; WHO-5, WHO Well-Being Index.